|
|||||
|
|
Preparation,characterisation and in vitro antibacterial property of ciprofloxacin-loaded nanostructured lipid carrier for treatment of Bacillus subtilis infection |
|
| Authors: | Petra Nnamani Agatha Ugwu Emmanuel Ibezim Simon Onoja Amelia Odo Maike Windbergs |
| Institution: | 1. Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Drug Delivery and Nanomedicines Research Group, University of Nigeria, Nsukka, Nigeria;2. Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarland University, Saarbrücken, Germany;3. petra.nnamani@unn.edu.ng obiomaeze@yahoo.com;4. Department of Human Nutrition and Dietetics, University of Nigeria, Nsukka, Nigeria;5. Department of Human Kinetics and Health Education, University of Nigeria, Nsukka, Nigeria;6. Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarland University, Saarbrücken, Germany |
| Abstract: | Context: In this study, controlled ciprofloxacin (CIPRO) nanostrustructured lipid carriers of Precirol® ATO 5/Transcutol® HP (batch A) and tallow fat/Transcutol® HP (batch B) was carreid out. Objective: The aim was to improve solubility and bioavailability of CIPRO. Objective: Study of controlled ciprofloxacin (CIPRO) nanostructured lipid carriers of Precirol® ATO 5/Transcutol® HP (batch A) and tallow fat/Transcutol® HP (batch B). Methods: CIPRO concentrations C1–5 (0.0, 0.2, 0.5, 0.8, and 1.0% w/w) as AC1–5 and BC1–5 were prepared by hot homogenisation and characterised by zetasizer, differential scanning calorimetry, Fourier transform infra-red spectroscopy, in vitro drug release and growth inhibitory zone diameter (IZD) on agar-seeded Bacillus subtilis. Results: AC5 achieved polydispersed particles of ～605?nm, 92% encapsulation efficiency (EE) and –28?mV similar to BC5 (～789?nm, 91% EE, and –31?mV). Crystallinity indices (AC5 and BC5) were low at 3 and 5%, respectively. CIPRO release in AC5 was ～98% in SGF (pH 1.2) and BC5 similarly ～98% in SIF (pH 6.8). Conclusions: AC5 had superior growth inhibition of B. subtilis at lower concentration (1.2 µg/mL) than BC5 and CIPRO controls; hence could serve as possible sustained delivery system of CIPRO. |
| Keywords: | Inhibition zone diameter ciprofloxacin Bacillus subtilis nanostructured lipid carriers antimicrobial activity |